GlassScriptPhysician profile
Dahlia Armas
NPI 1104463405
$969.98
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $954 · 2022: $15.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $142.96 | 2021 | |
| Pfizer INC. | $132.73 | 2021 | |
| Genzyme Corporation | $121.58 | 2021 | |
| Alk-Abello, INC | $116.01 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $106.87 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.56 | 2021 | |
| Optinose US, INC. | $59.68 | 2021 | |
| Glaxosmithkline, LLC. | $54.09 | 2021 | |
| Kaleo, INC. | $41.27 | 2021 | |
| Covis Pharma Gmbh | $33.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.62 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.18 | 2021 | |
| Aimmune Therapeutics, INC. | $16.59 | 2021 | |
| Biofrontera INC. | $15.50 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dahlia Armas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.